TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Glucocorticoid Receptor Antagonism in Subclinical Cushings

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible for inclusion if: they are males and over 18, lack clinical features classically associated with Cushing's syndrome; have evidence of excess circulating cortisol~Exclusion Criteria:~* Evidence of local or systemic malignancy; overt Cushing's syndrome; severe uncontrolled diabetes mellitus or hypertension; pregnancy; clinically significantly impaired cardiovascular function (e.g. stage IV cardiac failure); severe liver disease (liver enzymes ≥ 3 x the institutional upper limit of normal range); significantly impaired renal function (eGFR \<30/min); uncontrolled severe active infection; treatment with approved or experimental steroidogenesis inhibitors, adrenolytic agents, within four weeks of admission; In women, known endometrial cancer, history of endometrial hyperplasia or vaginal bleeding of unknown cause; requirement for inhaled or systemic glucocorticoids for existing disease; impaired mental capacity or markedly abnormal psychiatric evaluation that precludes informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Von Willebrand Disease (VWD) International Prophylaxis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Type 1: eligible for participation if~* ≤20% RCo and/or ≤20% FVIII; and~* DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; and~* Bleeding indication criteria are met~Type 2: eligible for participation if~* DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; or Type 2B;~* Bleeding indication criteria are met~Type 3: eligible for participation if~* Bleeding indication criteria are met~Bleeding Indication Criteria:~* Joint Bleeding: documentation of at least two apparently spontaneous bleeding episodes in the same joint in the six months prior to enrollment; or three or more apparently spontaneous bleeding episodes in different joints in the six months prior to enrollment.~* GI Bleeding: history of two or more severe GI bleeding episodes associated with either a drop in hemoglobin of ≥ 2 g/dl or requiring red blood cell transfusion or treatment with VWD concentrate.~* Failure to identify other causes of bleeding.~* Menorrhagia: a diagnosis of menorrhagia; prospectively completed Pictorial Blood Assessment Chart score \>185 or required treatment with a VWD product for menstrual bleeding on one or more occasions in the year prior to enrollment.~* Normal cervical cytology (PAP) within the six months prior to enrollment for females ≥ 18 years of age.~* Epistaxis 1. Three or more bleeding episodes in a six-month period that required treatment with VWD concentrates or red cell transfusions.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VWF/FVIII product infusions (Type: None): One to three infusions of factor replacement as needed to control bleeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Fasting plasma glucose within normal limits (80-100 mg/dl)~* BMI (Body Mass Index): 20.0-29.0 kg/m\^2 (inclusive)~* Heart rate within the range of 50-90 beats per minute (inclusive)~* Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data~Exclusion Criteria:~* Any clinically significant disease history, in the opinion of the investigator, of systemic or organ disease~* Any clinically significant disease history, in the opinion of the investigator, of cardiovascular disease~* Clinically significant abnormalities on any pre-study clinical examination or any abnormal laboratory measurements during screening~* A family history of sudden cardiac death at age less than 50 years old~* T-wave abnormalities~* Individual or familial history of long QT Syndrome~* Positive results on Screening for Hepatitis B surface antigen, Hepatitis C antibody or HIV (human immunodeficiency virus) antibody~* Positive results on the urine drug and alcohol screen~* Any regular use of prescription or nonprescription drugs or vitamins and herbal/nutritional supplements that cannot be stopped at screening~* Any strenuous exercise (as judged by the investigator) from 4 days prior to randomisation and during the entire trial period~* Blood donation, trauma or surgery with blood loss exceeding 500 ml within the last 2 months prior to dosing~* Subject is a smoker, occasional smoker or has a history of smoking (or use of any tobacco) within the last 3 months~* Excessive use of methylxanthine-containing beverages (more than 8 cups/day of coffee, tea, soda or chocolate)~* Females who are pregnant, breastfeeding, intend to become pregnant within the next 3 months, or who are judged to be using inadequate contraceptive measures~* A history (within the last 2 years) of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Double-blind / liraglutide (Type: EXPERIMENTAL): None
- Double-blind / placebo (Type: PLACEBO_COMPARATOR): None
- Open-label / moxifloxacin (Type: ACTIVE_COMPARATOR): None
- Open-label / placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* MS patients with any disease subtype who are ≥18 years of age and must have been newly prescribed Fampyra but not yet started the treatment.~* Patients who are willing and able to provide written informed consent.~Key Exclusion Criteria:~* None~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fampyra (Type: None): Fampyra administered as prescribed in routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* the subjects were HIV-seropositive by standard serum enzyme-linked immunosorbent assay (ELISA) tests and also by Western blot analysis~* the subjects were antiretroviral drug-naïve~* a baseline CD4+ T-cell count from 100 to 350 cells/mm3 and a baseline plasma viral load over 500copies/ml~Exclusion Criteria:~* pregnancy or breastfeeding~* anticipated nonadherence~* AIDS-defining illness within 2 weeks of entry~* white blood cell count less than 2.0×109/L, absolute neutrophil count less than 1.0×109/L, hemoglobin level less than 90g/l, platelet count less than 0.75×1012/L~* transaminase and alkaline phosphatase level more than 3 times the upper limit of the normal range, bilirubin level more than 2.5times the upper limit of the normal range, serum creatinine level more than 1.5 times the upper limit of the normal range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: EXPERIMENTAL): None
- A (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Visit 1:~  1. Written informed consent to participate in the trial (Appendix B)~ 2. Male or female subjects, age \> 18 years~ 3. Primary hypercholesterolaemia with CV risk \> 20%/10yrs, type 2 diabetes, a history of CHD or other established atherosclerotic disease (definition given in Appendix L).~ 4. Subjects may be lipid-lowering therapy-naïve, but have completed 6-weeks dietary counselling before this visit OR Subjects may be treated with the 'start' dose of other lipid lowering therapy, which is ineffective, ie. The subject has not met LDL-C treatment goals.~ 5. Subjects willing to follow all study procedures including attendance at clinics for scheduled study visits, fasting prior to blood draws and compliance with study treatment regimen~     Visit 2:~ 6. Subjects switched from start dose of a lipid lowering therapy (commonly accepted start dose) will have fasting LDL-C levels \> 3.1 mmol (120 mg/dl)~ 7. Newly treated subjects, after a six-weeks dietary counselling, will have fasting LDL-C levels \> 3.5 mmol/L (135 mg/dL)~ 8. Fasting triglycerides £ 4.52 mmol/L (400 mg/dL)~ 9. Switched patients must stop current lipid lowering treatment at randomisation (Visit 2)~Exclusion Criteria:~1. Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia)~2. Documented secondary hypercholesterolaemia of any cause other than named in inclusion criteria 3~3. History of serious adverse effect or hypersensitivity reactions to other HMG-CoA reductase inhibitors, in particular any history of myopathy~4. Unstable angina within three months prior to inclusion in the study~5. Active liver disease or hepatic dysfunction as defined by elevations of AST or ALT ³ 1.5 times the ULN. In this case, a second determination of hepatic tests will be performed after one week. If the dysfunction is confirmed, the subject must not be included in the study~6. Known uncontrolled diabetes~7. Uncontrolled hypertension defined as either resting diastolic blood pressure of \> 95mmHg or resting systolic blood pressure of \> 200 mmHg~8. Unexplained serum CK \> 3 times ULN (eg not due to recent trauma, intramuscular injections, heavy exercise etc)~9. Serum creatinine \> 220 µmol/L (2.5mg/dL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM, diagnosed at least 6 weeks prior to visit 1, who have had no treatment with oral antidiabetic agents for at least 12 weeks prior to study entry (visit 1) and no treatment with oral antidiabetic agents at any time in the past for \> 3 consecutive months~* \>/= 18 years~* Body mass index in the range of 22-35 kg/m2~* HbA1c \</=7.5%~Exclusion Criteria:~* Type 1 diabetes~* Acute metabolic diabetic complications~* Evidence of significant diabetic complications~* Insulin treatment within the past 6 months~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in the protocol).~* Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.~* Participants with a screening LCI2.5 result ≥7.5.~* Participants who are able to swallow tablets.~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension.~* Colonization with organisms associated with a more rapid decline in pulmonary status.~* Solid organ or hematological transplantation.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: OTHER): Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
- TEZ/IVA (Type: EXPERIMENTAL): Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
- Ivacaftor (Type: EXPERIMENTAL): Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The participants of this study were rheumatoid arthritis (RA) patients for whom adalimumab was prescribed. They must have met the following conditions:~* Disease duration of RA ≤2 years~* Methotrexate (MTX) administration ≥3 months prior to starting adalimumab~* Dose of MTX ≥12mg/week~* Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) score \>3.2~Exclusion Criteria:~* Participants who had been previously treated with biologics (including tumor necrosis factor \[TNF\] inhibitors and others)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants treated with adalimumab (Type: None): 40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged more than 18 years.~* Refractory or relapsed peripheral T-cell NHL (PTCL)~* Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy~* ECOG score less than 2~* No major organ dysfunction unrelated to lymphoma.~Exclusion Criteria:~* Pregnant or breast feeding women~* ECOG score \> 2~* Estimate survival time \< 3 months~* Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy~* Creatinine clearance \< 10 ml/min or severe hepatic dysfunction not related to lymphoma.~* Previous chemotherapy/immunotherapy within 3 weeks before study entry~* Known seropositive for or active viral infection HIV, EBV, HCV~* CNS lymphoma~* T-cell Leukemia lymphoma associated with HTLV1~* Sezary syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine (Type: EXPERIMENTAL): Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria (overall):~1. Adult (age ≥18 years)~2. ED patient at Intermountain Medical Center, Utah Valley Hospital, Dixie Regional Medical Center~3. Arrival to study emergency department (ED) during study period of 11/13/2018 to 2/12/2021.~Exclusion criteria (overall):~(1) Trauma patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-implementation usual care (intervention site) (Type: NO_INTERVENTION): Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
- Code Sepsis post-implementation (intervention site) (Type: EXPERIMENTAL): Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
- Pre-implementation usual care (control sites) (Type: NO_INTERVENTION): Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
- Post-implementation usual care (control sites) (Type: NO_INTERVENTION): Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medically recommended influenza A(H1N1) immunization~* signed informed consent~Exclusion Criteria:~* failure or refusal to provide sufficient blood for antibody determination

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High-risk patients ( 5 cohorts) (Type: EXPERIMENTAL): None
- Healthy controls (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Suspected diagnosis of NASH, evidenced by elevated alanine aminotransferase (ALT), liver stiffness compatible with F2 or F3 fibrosis and Liver Fat Content (LFC) ≥10% as measured by MRI~* Women of childbearing potential and male patients with female partners must agree to use a dual method of contraception~Exclusion Criteria:~* Evidence of worsening liver injury~* Previous diagnosis of other forms of non-NASH liver disease~* Use of Vitamin E, glitazones, glucagon-like Peptide-1 receptor agonists, ursodeoxycholic acid, or obeticholic acid within 90 days prior to screening~* History of cirrhosis or liver decompensation~* Known history of alcohol abuse or daily heavy alcohol consumption~* Pregnant or breastfeeding women~* Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus~* Patients with contraindications to MRI imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vonafexor 100 mg BID (Type: EXPERIMENTAL): Oral dose twice daily for 12 weeks (84 days)
- Vonafexor 200 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)
- Vonafexor 400 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)
- Placebo (Type: PLACEBO_COMPARATOR): Oral dose twice daily for 12 weeks (84 days)
- Vonafexor 100 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete